Treatment of metastatic malignant melanoma, Curr Treat Options Oncol, vol.6, pp.185-93, 2005. ,
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma, J Clin Oncol, vol.19, pp.3635-3683, 2001. ,
Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy, Eur J Immunol, vol.31, pp.2007-2022, 2001. ,
Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients, Cancer Immunol Immunother, vol.56, pp.515-541, 2007. ,
High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens, J Exp Med, vol.201, pp.241-249, 2005. ,
High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells, Clin Cancer Res, vol.6, pp.1459-67, 2000. ,
URL : https://hal.archives-ouvertes.fr/inserm-02482162
Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression, J Immunother, vol.28, pp.258-67, 2005. ,
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1, N Engl J Med, vol.358, pp.2698-703, 2008. ,
Detection of intracellular cytokines by flow cytometry, J Immunol Methods, vol.159, pp.197-207, 1993. ,
Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma, Cancer Immunol Immunother, vol.56, pp.1853-60, 2007. ,
Lymphocyte biomarkers of clinical responses to adoptive immunotherapy of malignant melanoma, Cur Cancer Ther Rev, vol.4, pp.125-134, 2008. ,
Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients, Cancer Immunol Immunother, vol.51, pp.532-540, 2002. ,
Frequency and relative fraction of tumor antigen-specific T cells among lymphocytes from melanoma-invaded lymph nodes, Int J Cancer, vol.78, pp.209-224, 1998. ,
Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma, J Clin Oncol, vol.24, pp.5060-5069, 2006. ,
Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients, J Immunol, vol.170, pp.2161-2170, 2003. ,
Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates, J Exp Med, vol.205, pp.625-665, 2008. ,
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues, J Immunol, vol.160, pp.1750-1758, 1998. ,
Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells, J Immunol, vol.175, pp.4797-805, 2005. ,
, , 2002.
, Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells, Proc Natl Acad Sci, vol.99, pp.16168-73
Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo, J Exp Med, vol.192, pp.1637-1681, 2000. ,
Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy, J Immunol, vol.175, pp.7046-52, 2005. ,